Search - tctmd.com

Displaying 121 - 140 of 387

Sort: Relevancy | Date

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Caitlin E. Cox

September 20, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Conference News SCAI 2019

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Yael L. Maxwell

May 30, 2019

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Caitlin E. Cox

May 23, 2019

Presentation SIF 2019

DAPT Duration and When to Switch to Antiplatelet Monotherapy Post PCI

Presenter: Michael A. Kutcher

March 28, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Opinion Editor's Corner ACC 2019

Live From New Orleans: Days 2 and 3 at ACC 2019

Shelley Wood

March 18, 2019

News Daily News

Current or Prior Cancers Affect PCI Outcomes Differently, Large Analysis Shows

L.A. McKeown

December 04, 2018

News Daily News

US and European DAPT Guidelines More Alike Than Different, Say Experts

Yael L. Maxwell

December 03, 2018

News Daily News

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Yael L. Maxwell

November 05, 2018

Presentation TCT 2018

Case #5: A Case in Which I Used OCT to Reduce DAPT Duration

Presenter: David Erlinge, Gary S. Mintz, Martin W. Bergmann, Marc D. Feldman, Margaret B. McEntegart, Yasunori Ueda, Carlo Zivelonghi, Robert-Jan van Geuns

September 24, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Advertisement

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

DAPT Duration and When to Switch to Antiplatelet Monotherapy Post PCI

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Live From New Orleans: Days 2 and 3 at ACC 2019

Current or Prior Cancers Affect PCI Outcomes Differently, Large Analysis Shows

US and European DAPT Guidelines More Alike Than Different, Say Experts

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Case #5: A Case in Which I Used OCT to Reduce DAPT Duration

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content